Punnett squares and phenotypes, chromatids and codominance: genetics, and all of its associated terms, isn’t the easiest field to understand....
Drugs with low oral bioavailability risk failure in clinical trial: minimal absorption, after all, can translate to reduced efficacy. As...
The US Patent Office has ruled “no interference in fact” on CRISPR-Cas9 Patent dispute.
Artificial intelligence is revolutionizing technology, but also medicine. Here’s how.
What exactly are mesenchymal stem cells … and more importantly, why should investors care?
Herceptin, Enbrel, Botox: at first glance, these therapies may appear to have little in common.
When generic competitors enter the market, sales from a blockbuster drug can decrease significantly.
From serums and masks to oral sprays and enriched waters, we’re counting down the novel ways in which some cannabis-based...
The body already has amazing regenerative abilities—can we not harness that power and, in turn, amplify it?
These three blockbuster drugs transformed pharmaceutical investing. But will we ever see anything like them again?